相关实验视频

Updated: Jun 23, 2025

Murine Model of CD40-activation of B cells

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

一种新型的抗CD38单克隆抗体用于治疗免疫性血小板缺血症

Yunfei Chen¹, Yanmei Xu¹, Huiyuan Li¹

¹From the National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, Chinese Academy of Medical Sciences Key Laboratory of Gene Therapy for Blood Diseases, and the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, and the Tianjin Institutes of Health Science, Tianjin (Y.C., Y.X., H.L., T.S., X.C., Y.W., F.X., W.L., X.L., H.D., R.F., X.D., W.W., Y.M., Z.S., Y.C., M.J., W.G., X.P., R.Y., L.Z.), and the School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (L.Z.) - all in China.

The New England journal of medicine

|June 20, 2024

概括

这项研究表明,CM313是一种抗CD38抗体,在免疫血小板缺血症 (ITP) 患者中有效增加了血小板计数. 该治疗证明了持续的疗效和可控的副作用,为ITP提供了一个有前途的新疗法.

科学领域:

免疫学免疫学免疫学
血液学血液学血液学
药理学药理学是指药理学的学科.

背景情况:

免疫性血小板缺血 (ITP) 是一种自身免疫性疾病,通过自身抗体引起血小板的破坏.
CM313是一种新的抗CD38单克隆抗体,向CD38阳性细胞,包括血细胞.

研究的目的:

评估CM313在患有ITP的成年患者中的安全性和有效性.
评估CM313对免疫细胞群和单核细胞系统的影响.

主要方法:

在22名成年ITP患者中,对CM313进行了1-2期的开放性研究.
静脉注射CM313每周16毫克/公斤,持续8周,随后进行16周的随访.
监测不良事件,血小板数,外围免疫细胞和ITP的小鼠模型.

主要成果:

95%的患者在8周内连续两次达到血小板计数≥50×10^9/L.
响应的平均持续时间为23周;响应的平均时间为1周.
常见的不良事件包括输液反应 (32%) 和上呼吸道感染 (32%).

结论:

抗CD38疗法通过抑制抗体依赖的细胞中介细胞毒性,迅速增加了血小板水平.
长期有效性通过血细胞枯竭保持,主要是低级毒性作用.
CM313代表了对免疫性血小板缺血的有前途的治疗选择.

更多相关视频

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants

Published on: August 9, 2019

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...